Profile

Cover photo
Biotech Beat
22 followers|30,410 views
AboutPostsPhotosVideos

Stream

Biotech Beat

Shared publicly  - 
 
"The reason I bring this up is that it reminds me of the power imbalance that used to exist between the big guys and the little guys in pharmaceuticals. For at least 10 years, the big guys (Big Pharma and Big Biotech) had the dominant upper hand in negotiations with small innovators. That’s no longer true. The little guy with a promising new drug candidate can walk away from a low-ball bid and go public now. The rising tide of the stock market has roughly doubled the group of companies that have the cash to buy innovative new drugs. The group of potential buyers is about twice as big as it was 3-5 years ago, according to a couple of venture capitalists I spoke with at JP Morgan."
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"In the world of biopharmaceuticals, there’s no such thing as a boring year. Yet even by those standards, 2013 may be a standout, as the sector saw explosive growth on the capital markets, witnessed burgeoning scientific advances reach maturation and encountered new regulatory challenges that will set the stage in the years to come. Trying to pick out the biggest breaking news stories and/or trends for the year proved a challenge, but BioWorld’s staff managed to whittle down the list to the top 10 we feel have had or will have the greatest impact on the industry."
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"Britain's AstraZeneca said on Tuesday it was aware South Korea's Hanmi Pharmaceutical had launched a competitor to its top selling stomach-acid drug Nexium in the United States.

A U.S. court in September lifted a temporary injunction stopping Hanmi launching its esomeprazole strontium product, a close relative of Nexium. The block had been imposed because of an ongoing legal dispute over AstraZeneca's patents.

Nexium sales are declining but the heartburn and ulcer treatment remains a major seller for Britain's second-biggest drugmaker, with worldwide sales in 2012 of $3.94 billion, of which $2.27 billion was generated in the United States."

#Nexium
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs.

OncoMed will get upfront payments of $177.25 million, including $22.25 million for new stock that would give Celgene a stake of about 5 percent, the companies said."
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"Merck & Co. (MRK:US)’s cancer drug being evaluated in nine different malignancies kept more than four of five melanoma patients alive for a year in a study, including some who had exhausted all other treatment options.

The research presented at the International Congress of the Society for Melanoma Research in Philadelphia found 41 percent responded to treatment and 9 percent showed evidence of the tumor disappearing. While the improvement emerged within three months for most patients, several responded more than six months later. One had a remission after 70 weeks of therapy."

#Merck   #melanoma  
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"Pharmacyclics Inc. won Food and Drug Administration approval Wednesday for its blood cancer drug.

Imbruvica, approved for patients previously treated with other drugs for mantle cell lymphoma, is the second drug from a Bay Area company to be green-lighted by the FDA under the agency's Breakthrough Therapy program. Along with the FDA's Nov. 1 OK of South San Francisco-based Genentech Inc.'s leukemia drug Gazyva, it is the only two drugs to win approval through the designation."
1
Add a comment...
In their circles
2 people
Have them in circles
22 people
Hipperquímica Equipamentos para Laboratorios's profile photo
Biotech 365's profile photo
Biotech Career's profile photo
Web design and software development's profile photo
Carissa Simmerman's profile photo
Clariant Cargo & Device Protection's profile photo
Rob Kazmierski's profile photo
Cold Chain IQ: Pharma Logistics & Quality's profile photo
Sentector's profile photo

Biotech Beat

Shared publicly  - 
 
"Biotechnology stocks have been among the best performing investment vehicles throughout much of 2013.  With the momentum still firmly in tact as we head into 2014, investors are likely licking their chops for additional gains.  Unfortunately, the industry does carry abnormal risk and four stocks suffered the cruel fate of failure in a year when it was hard not to win.  The four stocks that suffered catastrophic drops in value were Amarin Corporation (NASDAQ:AMRN), Ariad Pharmaceuticals (NASDAQ:ARIA), Celsion CLSN +0.78% Corporation (NASDAQ:CLSN), and Infinity Pharmaceuticals INFI +2.37% (NASDAQ:INFI)."
Biotechnology stocks have been among the best performing investment vehicles throughout much of 2013.  With the momentum still firmly in tact as we head into 2014, investors are likely licking their chops for additional gains.  Unfortunately, the industry does carry abnormal risk and four stocks suffered the cruel fate of [...]
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
On Friday, the Food and Drug Administration approved a pill called Orenitram, to treat pulmonary arterial hypertension. It is an oral version of an injected drug called Remodulin, which treats the same disease. According to Mark Schoenebaum at ISI Group, the approval is "an enormous surprise -- arguably, one of [...]
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said on Friday.

A Phase III trial found the drug, dubbed LBH589 when combined with bortezomib and dexamethasone, significantly extended progression-free survival in patients with relapsed or relapsed and refractory multiple myeloma compared to bortezomib and dexamethasone alone.

Multiple myeloma is a cancer that starts in plasma cells in bone marrow and disrupts the production of normal blood cells. It affects approximately 1 to 5 in every 100,000 people worldwide each year and typically occurs in those aged over 50."

#Novartis  #multiplemyeloma
ZURICH (Reuters) - An experimental drug from Novartis to treat a type of bone marrow cancer met its primary goal in a late-stage study, the Swiss drugmaker said on Friday.A Phase III trial found the drug,
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
Instantly connect to what's most important to you. Follow your friends, experts, favorite celebrities, and breaking news.
1
Add a comment...

Biotech Beat

Shared publicly  - 
 
"An experimental drug to treat a rare genetic disorder that causes skeletal malformation and a host of related lung, eye, ear and heart problems confers "modest" benefit, according to an initial review by the U.S. Food and Drug Administration.

The drug, Vimizim, is being developed by BioMarin Pharmaceutical Inc to treat Morquio A Syndrome, also known as MPS IV-A. BioMarin shares rose as much as 8 percent."
1
Add a comment...
People
In their circles
2 people
Have them in circles
22 people
Hipperquímica Equipamentos para Laboratorios's profile photo
Biotech 365's profile photo
Biotech Career's profile photo
Web design and software development's profile photo
Carissa Simmerman's profile photo
Clariant Cargo & Device Protection's profile photo
Rob Kazmierski's profile photo
Cold Chain IQ: Pharma Logistics & Quality's profile photo
Sentector's profile photo